Uric Acid Stones Clinical Trial
Official title:
Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation
Patients who are overweight or obese, diabetic or not, share with those who are suffering
from uric stones the same way to remove abnormal acidity of the body in urine, ie a kidney
ammoniogenesis default. This results in an overly acidic urine pH which is directly
pathogenic in people predisposed to develop uric stones because the precipitation of urate
soluble uric acid is accelerated in acid medium.
Excess visceral fat, particularly perirenal, this defect may promote formation of renal
ammonium. Indeed, the perirenal fat is adjacent to the renal cortex and shares with it a
common arterial supply via the plexus Turner. Adipokines and fatty acids of the perirenal fat
are predisposed to gain the renal cortex, seat of the ammoniogenesis. In humans the
pathogenic role of the perirenal fat is demonstrated in chronic kidney disease and essential
hypertension. However, the amount of fat and perirenal that of intra-abdominal fat are
positively correlated.
Investigators hypothesis is that the perirenal fat also exert a pathogenic role in uric
because of anatomical links between kidney stones and greasy environment and because excess
fatty acids reaching the renal cortex decreases ammoniogenesis in an animal model metabolic
syndrome.
For the test, the investigators will compare the amount of fat and perirenal renal ability to
form ammonium in patients with uric or calcium lithiasis taking into account the amount of
intra-abdominal fat.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06335537 -
Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers
|
Phase 1 | |
Recruiting |
NCT04621929 -
Obesity and Uric Acid Stones Study
|
Phase 3 | |
Recruiting |
NCT06118320 -
The Effective of Potassium Sodium Hydrogen Citrate in Treating Uric Acid Stones Using Gut Microbiota and Metabolomics.
|
||
Recruiting |
NCT04352153 -
Role of Uralyt-U in Patients With Hyperuricemia
|
N/A |